Apollo Cancer Centres pioneers CAR T Cell Therapy in India, Introduces Made in India CAR T Cell Program
Kolkata : Apollo Cancer Centres (ACCs) achieves a historic milestone as the first private hospital group in India to successfully complete CAR T Cell Therapy. Building on this achievement, ACCs introduces the Made in India CAR T cell program, starting with NexCAR19, targeting B-cell lymphomas and B-acute lymphoblastic leukemia in patients aged 15 years and above.
CAR T cell therapies, known as living drugs, involve extracting patients’ T-cells and genetically modifying them to express Chimeric Antigen Receptors (CARs) that recognize cancer cells. With over 25,000 patients worldwide benefiting from this therapy, Dr. Anupam Chakrapani, Senior Consultant – Haematology & BMT Specialist, ACC, Kolkata, emphasized its efficacy in challenging conditions.
Dr. Rajat Bhattacharyya, Senior Consultant – Pediatric Haematology, ACC, Kolkata, hailed the therapy’s potential in addressing B-cell malignancies, marking a significant advancement in cancer treatment in India.
Mr. Rana Dasgupta, CEO Eastern Region, ACC Kolkata, Apollo Hospitals Enterprises Limited, expressed commitment to groundbreaking healthcare, reinforcing Apollo’s dedication to innovation in cancer treatment. The introduction of Made in India CAR-T therapy signifies a new era in cancer care, promising better outcomes for patients nationwide.
